LSKL, Inhibitor of Thrombospondin (TSP-1) (TFA), CAS [[2828433-17-4]]

Produktübersicht

• Artikelname: LSKL, Inhibitor of Thrombospondin (TSP-1) (TFA), CAS [[2828433-17-4]]
• Artikelnummer: MCE-HY-P0299A
• Hersteller Artikelnummer: HY-P0299A
• Alternativnummer: MCE-HY-P0299A-10MG,MCE-HY-P0299A-25MG,MCE-HY-P0299A-5MG
• Hersteller: MedchemExpress
• Kategorie: Proteine/Peptide

Produktbeschreibung

LSKL, Inhibitor of Thrombospondin (TSP-1) TFA is a latency-associated protein (LAP)-TGFbeta derived tetrapeptide and a competitive TGF-beta1 antagonist. LSKL, Inhibitor of Thrombospondin (TSP-1) TFA inhibits the binding of TSP-1 to LAP and alleviates renal interstitial fibrosis and hepatic fibrosis. LSKL, Inhibitor of Thrombospondin (TSP-1) TFA suppresses subarachnoid fibrosis via inhibition of TSP-1-mediated TGF-beta1 activity, prevents the development of chronic hydrocephalus and improves long-term neurocognitive defects following subarachnoid hemorrhage (SAH). LSKL, Inhibitor of Thrombospondin (TSP-1) TFA can readily crosse the blood-brain barrier[1][2].

Produkteigenschaften

• Molekulargewicht: 572.62
• Reinheit: 99.21
• CAS Nummer: [2828433-17-4]
• Formel: C23H43F3N6O7
• Target-Kategorie: TGF-beta Receptor

Anwendungsbeschreibung

• Anwendungsbeschreibung: Peptides